About Cue Biopharma
Cue Biopharma is a company based in Cambridge (United States) founded in 2015. It operates as a HealthTech. Cue Biopharma has raised $10 million across 2 funding rounds from investors including MDB Capital Holdings. The company has 41 employees as of December 31, 2024. Cue Biopharma offers products and services including Engineered Biologics. Cue Biopharma operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Cambridge, United States
- Employees 41 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Cue Biopharma
-
Annual Revenue
$9.29 M69.16as on Dec 31, 2024
-
Net Profit
$-40.67 M19.83as on Dec 31, 2024
-
EBITDA
$-39.24 M19.18as on Dec 31, 2024
-
Total Equity Funding
$10 M (USD)
in 2 rounds
-
Latest Funding Round
$30 M (USD), Post-IPO
Nov 21, 2022
- Investors
-
Employee Count
41
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Cue Biopharma
Cue Biopharma is a publicly listed company on the NASDAQ with ticker symbol CUE in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Cue Biopharma
Cue Biopharma offers a comprehensive portfolio of products and services, including Engineered Biologics. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Engineered biologics are designed for immune system activation.
Unlock access to complete
Unlock access to complete
Funding Insights of Cue Biopharma
Cue Biopharma has successfully raised a total of $10M across 2 strategic funding rounds. The most recent funding activity was a Post-IPO round of $30 million completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Post-IPO — $30.0M
-
First Round
First Round
(15 Jun 2015)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2022 | Amount | Post-IPO - Cue Biopharma | Valuation |
investors |
|
| Jun, 2015 | Amount | Seed - Cue Biopharma | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Cue Biopharma
Cue Biopharma has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include MDB Capital Holdings. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage tech startups are funded by MDB Capital Holdings.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Cue Biopharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Cue Biopharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cue Biopharma Comparisons
Competitors of Cue Biopharma
Cue Biopharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cue Biopharma
Frequently Asked Questions about Cue Biopharma
When was Cue Biopharma founded?
Cue Biopharma was founded in 2015.
Where is Cue Biopharma located?
Cue Biopharma is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is Cue Biopharma a funded company?
Cue Biopharma is a funded company, having raised a total of $10M across 2 funding rounds to date. The company's 1st funding round was a Seed of $10M, raised on Jun 15, 2015.
How many employees does Cue Biopharma have?
As of Dec 31, 2024, the latest employee count at Cue Biopharma is 41.
What is the annual revenue of Cue Biopharma?
Annual revenue of Cue Biopharma is $9.29M as on Dec 31, 2024.
What does Cue Biopharma do?
Cue Biopharma is engaged in the development of engineered biologics aimed at mobilizing the patients immune system to treat serious diseases. The companys solutions are designed to selectively expand and activate specific immune cells while restoring immune balance. Their work primarily targets autoimmune and inflammatory diseases through innovative approaches in the biotechnology sector, with partnerships such as with Boehringer Ingelheim to advance next-generation treatments.
Who are the top competitors of Cue Biopharma?
Cue Biopharma's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Cue Biopharma offer?
Cue Biopharma offers Engineered Biologics.
Is Cue Biopharma publicly traded?
Yes, Cue Biopharma is publicly traded on NASDAQ under the ticker symbol CUE.
Who are Cue Biopharma's investors?
Cue Biopharma has 1 investor. Key investors include MDB Capital Holdings.
What is Cue Biopharma's ticker symbol?
The ticker symbol of Cue Biopharma is CUE on NASDAQ.